Weight regain after stopping GLP-1 therapy is now one of the most pressing questions in obesity care — real-world data shows most patients regain the majority of lost weight within a year of discontinuation. This session presents outcomes comparing regain trajectories and impact on disease reversal between patients who received structured wraparound care alongside their medicated pathway and those who didn't, and asks what this means for how NHS-commissioned services should be designed as GLP-1 prescribing scales.